Human PAI2 (Plasminogen Activator Inhibitor 2 ) CLIA Kit
The Human PAI-2 (Plasminogen Activator Inhibitor-2) CLIA Kit is a highly accurate and reliable tool for measuring PAI-2 levels in human biological samples such as serum and plasma. This kit offers exceptional sensitivity and specificity, ensuring precise and reproducible results for a variety of research applications.PAI-2 is a key regulator of the fibrinolytic system, controlling the activity of plasminogen activators and influencing processes such as blood clot formation and tissue remodeling.
Dysregulation of PAI-2 has been associated with various diseases, including thrombosis, inflammation, and cancer, making it a valuable biomarker for studying these conditions and developing potential therapeutic interventions.The Human PAI-2 CLIA Kit from Assay Genie provides researchers with a powerful tool for investigating the role of PAI-2 in health and disease, offering a comprehensive solution for reliable and accurate measurement of this important protein.
Product Name:
Human PAI2 (Plasminogen Activator Inhibitor 2 ) CLIA Kit
SKU:
HUES01123
Target:
Human PAI2 (Plasminogen Activator Inhibitor 2 )
Size:
96T
Assay type:
Sandwich
Assay time:
4.5h
Sensitivity:
0.19 ng/mL
Detection range:
0.31-20 ng/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
CLIA Plate
8 wells x 3 strips
8 wells x 12 strips
-20°C, 6 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 6 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 6 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent A
1 vial, 5 mL
1 vial, 5 mL
4°C (shading light)
Substrate Reagent B
1 vial, 5 mL
1 vial, 5 mL
Desiccant
1
1
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human PAI2. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human PAI2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human PAI2, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human PAI2. You can calculate the concentration of Human PAI2 in the samples by comparing the RLU value of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
100-116
92-103
99-110
Average (%)
106
98
105
1:4
Range (%)
95-111
87-103
84-95
Average (%)
103
94
90
1:8
Range (%)
96-112
100-116
87-100
Average (%)
103
107
93
1:16
Range (%)
85-100
85-97
89-104
Average (%)
91
91
95
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
88-104
95
EDTA plasma (n=5)
90-106
97
Cell culture media (n=5)
88-99
93
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20.0
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
1.01
1.74
7.41
1.03
1.9
7.42
Standard deviation
0.11
0.2
0.78
0.13
0.15
0.53
C V (%)
10.89
11.49
10.53
12.62
7.89
7.14
Sample type &Sample volume:
Serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 15%.
Application:
This CLIA kit applies to the in vitro quantitative determination of Human PAI2 concentrations in Serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human PAI2 in samples. No significant cross-reactivity or interference between Human PAI2 and analogues was observed.
